Andre Vivan da Silva – Country Manager, GSK Brazil
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Address: Estrada dos Bandeirantes 8464 – Rio de Janeiro – RJ CEP 22783-110.
CNPJ 33.247743/0001-10
Estrada dos Ba,Brazil
Tel: 0800 701 22 33
GlaxoSmithKline (GSK) is a world leader in creating therapeutic solutions that help improve the quality of life. In Brazil since 1908, it operates in the areas of pharmaceuticals, vaccines, consumption and global production and supply, and research and development in the pharmaceutical and biological.
In 2009, GSK had sales total 28.4 billion pounds, including medicines, vaccines and consumer products to health care. Distributing its products in 130 countries, GlaxoSmithKline has a staff of 100,000 people worldwide.
The company’s world headquarters is located in the United Kingdom and its operational center in the United States. The regional headquarters is located in Latin America in Rio de Janeiro, Brazil.
anti-infective, central nervous system, respiratory and gastrointestinal / metabolic
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
Marlene Oliveira, founder and president of the Instituto Lado a Lado Pela Vida (Side by Side for Life) documents the main objectives and achievements of this Brazilian institution of reference,…
Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in…
Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil,…
Haig Yeghiaian, country manager of LEO Pharma Brazil, details his strategic mission and objectives since he took over the helm of the affiliate in November 2016 as well as the…
In an exclusive interview, Minister of Health of Brazil Ricardo Barros provides insights into his main achievements since being appointed in May 2016 and his key priorities to further improve…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
See our Cookie Privacy Policy Here
